As of August 14, 2019, Cavion is a wholly-owned subsidiary of Jazz Pharmaceuticals plc, an international biopharmaceutical company dedicated to developing life-changing medicines for people with limited or no options. Living our core values of integrity, passion, collaboration, innovation, and the pursuit of excellence is the key to our success. Read more about Jazz Pharmaceuticals: https://www.jazzpharma.com.
Cavion is a clinical-stage pharmaceutical company with an innovative mindset and compassionate culture. Cavion closed a Series A venture capital financing in late 2016. Combining those investors’ industry capabilities with Cavion’s science and expertise has put us well on the road to developing our promising Cav3 modulators for movement disorders and rare, pediatric epilepsies. Committed to putting people in the center, Cavion’s first neurology clinical trial – the T-CALM trial of CX-8998 in essential tremor – is now recruiting subjects.